伊布替尼
医学
内科学
安慰剂
危险系数
慢性淋巴细胞白血病
临床终点
不利影响
随机对照试验
肿瘤科
白血病
置信区间
病理
替代医学
作者
Petra Langerbeins,Can Zhang,Sandra Robrecht,Paula Cramer,Moritz Fürstenau,Othman Al‐Sawaf,Julia von Tresckow,Anna‐Maria Fink,Karl‐Anton Kreuzer,Ursula Vehling‐Kaiser,Eugen Tausch,Lothar Müller,Michael Josef Eckart,Rudolf Schlag,Werner Freier,Tobias Gaska,Christina Balser,Marcel Reiser,Martina Beate Stauch,Clemens‐Martin Wendtner
出处
期刊:Blood
[Elsevier BV]
日期:2021-11-11
卷期号:139 (2): 177-187
被引量:108
标识
DOI:10.1182/blood.2021010845
摘要
Observation is the current standard of care for patients with early-stage asymptomatic chronic lymphocytic leukemia (CLL), as chemotherapy-based interventions have failed to prolong survival. We hypothesized that early intervention with ibrutinib would be well tolerated and lead to superior disease control in a subgroup of early-stage patients with CLL. The phase 3, double-blind, placebo-controlled CLL12 trial randomly assigned asymptomatic, treatment-naïve Binet stage A CLL patients at increased risk of progression in a 1:1 ratio to receive ibrutinib (n = 182) or placebo (n = 181) at a dose of 420 mg daily. At a median follow-up of 31 months, the study met its primary endpoint by significantly improving event-free survival in the ibrutinib group (median, not reached vs 47.8 months; hazard ratio = 0.25; 95% confidence interval = 0.14-0.43, P < .0001). Compared with placebo, ibrutinib did not increase overall toxicity, yielding similar incidence and severity of adverse events (AEs). The most common serious AEs were atrial fibrillation, pneumonia, and rash in the ibrutinib group, and basal cell carcinoma, pneumonia, and myocardial infarction in the placebo group. Ibrutinib-associated risk for bleeding (33.5%) was decreased by prohibiting the use of oral anticoagulants through an amendment of the study protocol and by avoiding CYP3A4 drug-drug interactions. Ibrutinib confirms efficacy in CLL patients at an early stage with an increased risk of progression. However, the results do not justify changing the current standard of "watch and wait." This trial was registered at www.clinicaltrials.gov as #NCT02863718.
科研通智能强力驱动
Strongly Powered by AbleSci AI